A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
about
Trastuzumab-containing regimens for metastatic breast cancerNanomedicine in the diagnosis and therapy of neurodegenerative disorders.Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series.Immunological Approaches in the Treatment of Metastasized Breast CancerLong-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registryCell-mediated drug delivery.Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes.Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series.Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.Trastuzumab in the management of early and advanced stage breast cancer.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Lack of uniformity in cardiac assessment during trastuzumab therapy.Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis.Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.Metastasiertes MammakarzinomTherapeutic options for metastatic breast cancerTreatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer
P2860
Q24194019-91B7FA80-67E7-473B-82AE-B0B24CA5F9DDQ33726019-25A9227C-1121-4087-ACE5-830EC4042170Q33827808-65AB9C56-EB7E-4CDC-9D3D-9FA4F25869FFQ33839341-316B6449-78DB-400B-95D5-9218DEA87089Q34140043-11481859-AA31-496C-B615-FDC59CE77962Q34503715-F5A445A5-7B87-4669-B3C0-E2B674BA0890Q34709440-E099EAE7-CF52-4A8D-B4AE-B46D87D2A75BQ35142235-2ECDF160-7B40-48A8-BFF4-F3467DC55C98Q35875708-2A256B5B-361F-4769-A72A-C01D2B532308Q36408570-53332464-1461-4FE3-ADFE-CE4747E98255Q36561648-6E78FA58-666D-40F8-8A36-2FAE3A2CE335Q37205811-E8DE0522-7596-4211-87C0-3DB41B0B707FQ37290613-575744B6-A3AC-4DB0-BD96-5174FDD10670Q37970020-F538752D-84EE-4E0F-B257-6E94E5DDBB68Q39746124-1CCF67A8-83C9-4228-91AD-6AD5C8225D8DQ44981087-4874BD2B-59B6-424F-8623-8ADFF03FAA8CQ54484711-B4321B27-62B6-4B6A-ABF4-1365C20F8095Q56624496-F817129E-DD04-4D49-A739-71718A63C54BQ57142375-6A013A8D-48D6-4C2F-9344-583A0B9BF285Q57578932-5AEFBBA5-DB71-464D-875B-D41359DB2BF3
P2860
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A phase II study on metastatic ...... tory of HER2-positive disease.
@en
A phase II study on metastatic ...... tory of HER2-positive disease.
@nl
type
label
A phase II study on metastatic ...... tory of HER2-positive disease.
@en
A phase II study on metastatic ...... tory of HER2-positive disease.
@nl
prefLabel
A phase II study on metastatic ...... tory of HER2-positive disease.
@en
A phase II study on metastatic ...... tory of HER2-positive disease.
@nl
P2093
P356
P1433
P1476
A phase II study on metastatic ...... tory of HER2-positive disease.
@en
P2093
A M Cianciulli
B Di Cocco
F Cognetti
G Ferretti
M Mottolese
P304
P356
10.1093/ANNONC/MDJ110
P577
2006-01-12T00:00:00Z